Figure 2.
Figure 2. Cumulative incidence of VTE according to patient-related factors and CLL-specific markers. Shown are cumulative incidences of VTE in 4 different exposure categories; all patients are thus at risk in 1 of the 2 groups in each exposure category. CLL patients without a second primary cancer (yet) contributed to number at risk of VTE from the CLL diagnosis date (t0); death and second primary cancer were treated as competing risks. CLL patients exposed to a second primary cancer contributed to number at risk of VTE from the second primary cancer diagnosis date (t0); death was treated as a competing risk (A). Too few events among CLL patients with Binet C, when a second primary cancer was treated as a competing risk, precluded a separate graph for this group (B).

Cumulative incidence of VTE according to patient-related factors and CLL-specific markers. Shown are cumulative incidences of VTE in 4 different exposure categories; all patients are thus at risk in 1 of the 2 groups in each exposure category. CLL patients without a second primary cancer (yet) contributed to number at risk of VTE from the CLL diagnosis date (t0); death and second primary cancer were treated as competing risks. CLL patients exposed to a second primary cancer contributed to number at risk of VTE from the second primary cancer diagnosis date (t0); death was treated as a competing risk (A). Too few events among CLL patients with Binet C, when a second primary cancer was treated as a competing risk, precluded a separate graph for this group (B).

Close Modal

or Create an Account

Close Modal
Close Modal